Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GE Healthcare announces takeover of Asymptote

GE Healthcare announces takeover of Asymptote

12th April 2017

GE Healthcare has announced the acquisition of Asymptote, a purchase that will strengthen its capabilities in the field of cell therapy.

Asymptote is a UK-based provider of cryochain technology for sensitive cellular therapies, with its integrated suite of cryochain hardware, software and consumables designed to maintain the potency of therapies undergoing ultra-low-temperature freezing.

Its innovative, digitally-enabled hardware are compliant with Current Good Manufacturing Practices and can significantly lower the risk of contamination found in conventional processes, while offering provide exceptional control and analytics in cryochain procedures.

Ger Brophy, general manager of GE Healthcare's cell therapy business, said: "Asymptote's high-quality offering takes us another step forward in our vision to industrialise cell therapy, and in providing reliable and high-quality services for our customers and patients around the world."

This follows other recent acquisitions in the field of cell therapy by GE Healthcare, including the purchases of Biosafe, Vitruvian Networks and the BridGE@CCRM Cell Therapy Centre of Excellence.

The cell therapy oncology market alone is expected to reach a value of $30 billion (23.98 billion pounds) by 2030.

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801834689-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.